Azole antifungal resistance has emerged as a significant problem in the management of infections caused by a number of fungal species including Candida. This problem has had a significant impact in immunocompromised patient populations, particularly those suffering from AIDS. While the use of highly active antiretroviral therapy (HAART) has reduced the frequency of OPC among AIDS patients in the United States, limited access to such therapy in underdeveloped countries, poor compliance, and toxicity associated with HAART will likely contribute to an increase in this problem among AIDS patients world-wide. Understanding the molecular basis of azole resistance will facilitate the development of therapeutic strategies to circumvent this problem and improve the utility of the azole class of antifungal agents.
The aim of this proposal is to identify and characterize novel molecular mechanisms of azole antifungal resistance in Candida albicans. The central hypothesis behind this proposal is that specific molecular mechanisms are responsible for the stepwise acquisition of azole antifungal resistance in C. albicans. We will use an integrated functional genomic and proteomic approach to characterize and compare the gene expression and proteomic profiles of serial isolates within and between multiple matched sets of azole-susceptible and -resistant isolates of C. albicans. These studies will identify genes and gene products that are associated with the azole resistance phenotype. They will also identify genes and gene products that are coordinately regulated with known resistance mechanisms and hence lend insight into the regulation of these mechanisms. We will also screen azole resistant isolates for genes required for this phenotype using an antisense cDNA library. Targeted gene disruption and over-expression will be used to assess the role of candidate resistance genes in this process. These mutants will then be examined for changes in in vitro azole susceptibility, and in certain cases for secondary effects on the azole resistance gene expression and proteomic profile. Additional studies will examine the nucleotide sequences of key genes for point mutations that may play a role in this process. These studies will further elucidate the molecular basis for azole antifungal resistance and will identify novel targets for future work towards the development of compounds that will both abrogate resistance and enhance the utility of the azole class of antifungal agents.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI058145-01A1
Application #
6824742
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Program Officer
Duncan, Rory A
Project Start
2004-07-01
Project End
2005-05-31
Budget Start
2004-07-01
Budget End
2005-05-31
Support Year
1
Fiscal Year
2004
Total Cost
$292,000
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Other Health Professions
Type
Schools of Pharmacy
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Popp, Christina; Hampe, Irene A I; Hertlein, Tobias et al. (2017) Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains. Antimicrob Agents Chemother 61:
Ramírez-Zavala, Bernardo; Mogavero, Selene; Schöller, Eva et al. (2014) SAGA/ADA complex subunit Ada2 is required for Cap1- but not Mrr1-mediated upregulation of the Candida albicans multidrug efflux pump MDR1. Antimicrob Agents Chemother 58:5102-10
Ofir, Ayala; Hofmann, Kay; Weindling, Esther et al. (2012) Role of a Candida albicans Nrm1/Whi5 homologue in cell cycle gene expression and DNA replication stress response. Mol Microbiol 84:778-94
Sasse, Christoph; Schillig, Rebecca; Dierolf, Franziska et al. (2011) The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans. PLoS One 6:e25623
Schubert, Sabrina; Barker, Katherine S; Znaidi, Sadri et al. (2011) Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents Chemother 55:2212-23
Schubert, Sabrina; Popp, Christina; Rogers, P David et al. (2011) Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1. Eukaryot Cell 10:1110-21
Mogavero, Selene; Tavanti, Arianna; Senesi, Sonia et al. (2011) Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1. Antimicrob Agents Chemother 55:2061-6
Heilmann, Clemens J; Schneider, Sabrina; Barker, Katherine S et al. (2010) An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob Agents Chemother 54:353-9